BioNTech
By therapeutic area
| Therapeutic area | Premium | Deals |
|---|---|---|
| oncology | ×1.27 | 3 |
By stage at signing
Not enough phase-specific data (need ≥3 deals per phase).
Strategy profile
Based on 15 disclosed transactions, BioNTech concentrates its licensing activity in Oncology, Other, and InfectiousDisease. BioNTech pays a 1.27x premium over market median, with the strongest premiums in Oncology (1.27x). Their most common deal structure is License, with an average disclosed value of $1.8B. Most recent activity: 2025.
Premium by therapeutic area
How BioNTech pays relative to peer medians in each TA
Pipeline coverage & gaps
BioNTech has disclosed activity in 1 of 12 tracked therapeutic areas. Gaps may represent whitespace opportunities for licensors.
Deal type breakdown
How this buyer structures its transactions
| Deal type | Count | Avg upfront | Avg total value |
|---|---|---|---|
| LicensePrimary | 8 | $347M | $2.7B |
| Acquisition | 3 | $632M | $973M |
| Collaboration | 3 | $180M | $624M |
| Option | 1 | $50M | $632M |
Recent disclosed deals
| Year | Asset | Licensor | Indication | Phase | Upfront | Total |
|---|---|---|---|---|---|---|
| 2025 | PD-L1/VEGF-A antibody | BMS | oncology | unknown | $1.5B | $11.1B |
| 2025 | CureVac N.V. (company; mRNA platform) | CureVac | — | unknown | — | $1.3B |
| 2024 | mRNA COVID-19 vaccine technology (Comirnaty) | University of Pennsylvania | covid-19 | approved | $400M | $467M |
| 2024 | solid_tumors | MediLink Therapeutics | solid_tumors | preclinical | $25M | $1.8B |
| 2024 | Biotheus (BNT327/PM8002, PD-L1 x VEGF-A bispecific) | Biotheus | solid_tumors | phase_2 | $800M | $950M |
| 2024 | Aucatzyl (obecabtagene autoleucel) | Autolus Therapeutics | B-ALL | approved | $250M | $250M |
| 2024 | obe-cel, AUTO1/22, AUTO6NG | Autolus Therapeutics plc | — | preclinical | $50M | $632M |
| 2024 | Obe-cel (obecabtagene autoleucel) and CAR-T platform technologies | Autolus Therapeutics | B-cell ALL and broader hematologic/solid tumor applications | phase_3 | $250M | $832M |
| 2023 | DB-1303, DB-1311 | Duality Bio | Multiple solid tumors | phase_1 | $170M | $1.7B |
| 2023 | DB-1303/BNT-163 and DB-1311/BNT-162 | Duality Biologics | HER2-directed solid tumors | phase_1 | $170M | $1.7B |
| 2023 | DB-1303 and DB-1311 | DualityBio | HER2-expressing solid tumors including HER2-low | phase_1 | $170M | $1.7B |
| 2023 | DB-1303 and DB-1311 | Duality Biologics (Suzhou) Co. Ltd. | HER2-expressing advanced solid tumors | phase_2 | $170M | $1.7B |
| 2023 | InstaDeep | InstaDeep | — | discovery | $463M | $719M |
| 2022 | solid_tumors | Duality Biologics | solid_tumors | phase_1 | $170M | $1.5B |
| 2022 | Humabody VH platform (T-cell engagers) | Crescendo Biologics | solid_tumor | discovery | $40M | $790M |
How this is computed
For each BioNTech deal we find the median total deal value of comparable transactions (same therapeutic area + phase, falling back to TA-only with ≥3 peers). The buyer’s deal divided by the peer median is the per-deal premium. We trim outliers, take the trimmed mean, and clamp to [0.7×, 1.5×] to reject data errors. Confidence scales with sample size.
Trimmed mean of 3 disclosed deal premiums vs. peer medians. Raw premium 1.267, clamped to [0.7, 1.5].